Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
maraviroc · 1 trial · 2 indications
Percentage of participants with confirmed plasma HIV-1 RNA \> 50 copies/mL
| Arm | Type | Description |
|---|---|---|
| Maraviroc plus darunavir/ritonavir | EXPERIMENTAL | Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks |
| Name | Type | Description |
|---|---|---|
| maraviroc | DRUG | 150 mg tab by mouth once daily for 96 weeks |
| darunavir | DRUG | 800 mg tab by mouth once daily for 96 weeks |
| ritonavir | DRUG | 100 mg capsule by mouth once daily for 96 weeks |
Inclusion Criteria: * HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA any time prior to study entry * Plasma HIV-1 RNA 5, 000 to 500,000 copies/mL obtain...
Top 20 of 28 competitors
Maraviroc is a small molecule being studied for the treatment of HIV-1 infection. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being evaluated in combination with other antiretroviral agents for patients with R5-tropic HIV-1.
Maraviroc is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with HIV-1 infection.
Maraviroc is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a completed Phase 2 trial for the treatment of HIV-1 infection.
Maraviroc has been studied in one completed clinical trial, identified as NCT00993148. This Phase 2 trial evaluated maraviroc in combination with darunavir and ritonavir for treatment-naïve patients infected with R5-tropic HIV-1. The trial enrolled 25 participants in the United States.
Maraviroc is a distinct investigational drug being developed by Pfizer. It is being studied specifically for HIV-1 infection and is not known to be the same as any other approved medication. Its mechanism of action and clinical profile are unique among antiretroviral therapies.